| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.3 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.085 | 0.3 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.3 |